Every Form 4 that Pulse Biosciences, Inc (PLSE) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PLSE and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PLSE filings page.
PULSE BIOSCIENCES, INC. (PLSE) Chief Operating Officer Liane Rae Teplitsky reported open-market purchases of company common stock. On August 31, 2026, she purchased 1,024 shares at a weighted average price of about $48.80 per share, in trades executed between $48.76 and $48.80. On September 1, 2026, she purchased an additional 1,001 shares at $49.95 per share. All trades were made in an open trading window under the company’s Insider Trading Policy, and no Rule 10b5-1 trading plan is reported.
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Operating Officer Liane Rae Teplitsky purchased common stock in two open-market transactions. On August 26, 2026 she bought 1,036 shares at $48.235 per share, and on August 28, 2026 she bought 1,034 shares at $48.35 per share, during an open trading window under the company’s Insider Trading Policy. Fractional-share amounts were rounded down, and same-price trades on each day were aggregated into single reported lines.
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Operating Officer Liane Rae Teplitsky received equity awards on August 8, 2026. She was granted 200,000 Restricted Stock Units, each representing one share of common stock, and 700,000 stock options with an exercise price of $19.06 per share. The RSUs vest upon performance-based criteria set by the board. Two sevenths of the option shares vest in equal installments on each of the first four anniversaries of the grant date, with the remainder vesting upon achieving performance targets tied to company market capitalization and GAAP product revenue, subject to continued service.
PULSE BIOSCIENCES, INC. (PLSE) reported that Chief Financial Officer Jon Skinner received a grant of stock options for 300,000 shares of common stock on February 3, 2025. The options have an exercise price of $20.93 per share and expire on February 3, 2035. Half of the options vest in equal installments over four years, and the remaining half vest in tranches tied to performance goals based on the company’s market capitalization between $2 billion and $5 billion and GAAP revenue targets between $48 million and $175 million, subject to his continued service.
PULSE BIOSCIENCES, INC. director Mahkam Zanganeh reported receiving two stock option grants. The options cover 14,504 and 30,000 shares of common stock at an exercise price of $26.89 per share and expire on June 11, 2036.
The 14,504-share option vests in equal monthly installments over one year starting on July 11, 2026, subject to continued service. The 30,000-share option vests in equal quarterly installments over one year starting on September 5, 2026. These are compensation-related awards, not open-market share purchases or sales.
PULSE BIOSCIENCES, INC. director Richard van den Broek reported receiving two stock option grants. Each option is a right to buy Common Stock at an exercise price of $26.89 per share and expires on June 11, 2036.
One option covering 8,423 shares vests in equal monthly installments over one year starting on July 11, 2026, subject to his continued service. The other option covering 30,000 shares vests in equal quarterly installments over one year starting on September 5, 2026, also contingent on continued service. These are compensation-related awards, not open-market purchases or sales.
PULSE BIOSCIENCES, INC. director and 10% owner Robert W. Duggan received two stock option grants as equity compensation. He was awarded options for 12,495 shares and 30,000 shares of common stock at an exercise price of $26.89 per share, expiring on June 11, 2036. The options vest over one year, with one grant vesting in equal monthly installments starting on July 11, 2026 and the other vesting in equal quarterly installments starting on September 5, 2026, subject to his continued service.
Pulse Biosciences director Manmeet Singh Soni received a grant of stock options, not a share purchase. The award covers 30,000 options to buy Common Stock at an exercise price of $26.89 per share, expiring on June 11, 2036. These options vest in equal monthly installments over one year, starting on July 11, 2026, contingent on continued service, leaving Soni with 30,000 derivative securities after the grant.
PULSE BIOSCIENCES, INC. director Maria Sainz reported receiving two grants of stock options on June 11, 2026. The awards cover 3,793 and 30,000 options to buy common stock at an exercise price of $26.89 per share and expire on June 11, 2036.
According to the disclosures, 3,793 options vest in equal monthly installments over one year starting July 11, 2026, while 30,000 options vest in equal quarterly installments over one year starting September 5, 2026. These are compensation-related grants, not open‑market stock purchases or sales.
PULSE BIOSCIENCES, INC. director and major shareholder Robert W. Duggan reported an open-market purchase of 660,233 shares of common stock at $19.69 per share. After this purchase, he directly owns 48,370,047 common shares.
He also has indirect holdings of 630,109 shares through Genius 24C Inc. and 450,189 shares through Blazon Corporation, where he is the sole shareholder. The shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC and include approximately 700 shares that were previously omitted from a Schedule 14A.
PULSE BIOSCIENCES, INC. director and Chief Executive Officer Paul A. LAVIOLETTE bought 15,000 shares of common stock in an open-market purchase on May 11, 2026 at $19.69 per share. After this transaction, he directly owns 15,846 shares of the company’s stock.
Footnotes explain the shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC, during an open trading window under the insider trading policy. His holdings also include shares purchased through the company’s Employee Stock Purchase Plan in March 2026.
PULSE BIOSCIENCES, INC. Chief Executive Officer Paul A. Laviollette purchased 15,000 shares of the company’s common stock in an open-market transaction. The shares were bought at a price of $19.69 per share and are held directly, bringing his direct ownership to 15,000 shares.
According to the disclosure, the shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC. The purchases occurred during an open trading window and in line with the company’s Insider Trading Policy and applicable securities laws.
PULSE BIOSCIENCES, INC. director and more than 10% owner Robert W. Duggan bought 660,233 shares of common stock in an open-market purchase at $19.69 per share. After this transaction, he directly owns 48,211,433 shares, with additional indirect holdings of 450,189 shares via Genius 24C Inc. and 630,109 shares via Blazon Corporation. The shares were acquired through the company’s at-the-market equity offering program under an Equity Distribution Agreement with TD Securities (USA) LLC and were purchased during an open trading window in line with the company’s insider trading policy.
UECKER DARRIN reported acquisition or exercise transactions in this Form 4 filing.
PULSE BIOSCIENCES, INC. reported that Chief Technology Officer Darrin Uecker received a grant of 100,000 Restricted Stock Units. Each RSU represents a contingent right to receive one share of common stock. Following this grant, he holds 100,000 RSUs.
The RSUs are scheduled to fully vest on March 23, 2029, the three-year anniversary of the grant, provided he continues to serve with the company through that date. This is a stock-based compensation award rather than an open-market share purchase or sale.
PULSE BIOSCIENCES, INC. Chief Commercial Officer Kevin Patrick Danahy exercised options and sold shares on February 18, 2026 under a pre‑arranged Rule 10b5‑1 trading plan adopted on May 14, 2025.
He exercised stock options for 5,000 shares at an exercise price of $1.53 per share and received 5,000 shares of common stock. He then sold 5,000 common shares in the open market at a weighted average price of $23.64 per share, with individual sale prices ranging from $22.40 to $24.40. After these transactions, he directly owned 43,298 common shares and held 300,000 stock options.
PULSE BIOSCIENCES, INC. Chief Commercial Officer Kevin Patrick Danahy exercised stock options and sold shares in mid-February. He exercised options covering 60,000 shares of Common Stock at a strike price of $1.53 per share and sold 60,000 shares in open-market transactions at weighted average prices of $23.37, $23.53, and $23.63 per share.
These trades were executed under a Rule 10b5-1 trading plan adopted on May 14, 2025. Following the transactions, Danahy directly holds 43,298 shares of Common Stock and 305,000 stock options from a 2022 grant for up to 450,000 shares that vests over four years.
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy reported a series of option exercises and share sales in Pulse Biosciences, Inc. common stock. On February 9, 10, and 11, 2026, he exercised 20,000 stock options at an exercise price of $1.53 per share each day, converting them into 20,000 common shares per day.
On each of those same dates, he then sold 20,000 common shares in open-market transactions at weighted average prices of $21.45, $23.52, and $25.20 per share, respectively, leaving 43,298 common shares held directly after each day’s sale. These trades were carried out under a Rule 10b5‑1 trading plan adopted on May 14, 2025.
Following the reported transactions, Danahy directly holds 365,000 stock options with an exercise price of $1.53 per share, originally granted on September 23, 2022 for up to 450,000 shares, with 25% vesting on each anniversary of the grant date.
Pulse Biosciences director Maria Sainz received new stock options in early 2026. On January 8, 2026, she was granted options to buy 50,000 shares of common stock at $14.72 per share. On February 5, 2026, she received options for 3,104 shares at $13.69 per share.
One-third of the 50,000-share grant will vest on the one-year anniversary of the grant, with the rest vesting monthly over the following two years, assuming continued service. The 3,104-share grant will vest in equal installments on March 5, 2026 and June 5, 2026, also conditioned on continued service.